| 1,4-Butanediol | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| 2-Aminoindane | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 2-FA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 2-FEA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 2-FMA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 2,5-DMA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 2C-H | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 2M2B | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| 3-FA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 3-FEA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 3-FMA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 3-FPM | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 3-MMC | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 3,4-CTMP | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 4-FA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 4-FMA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 4-MMC | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 4F-EPH | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 4F-MPH | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 5-APB | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 6-APDB | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| 8-Chlorotheophylline | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| A-PHP | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| A-PVP | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Acetylfentanyl | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Adrafinil | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Alcohol | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Alprazolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Amphetamine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Armodafinil | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Atropa belladonna | Dangerous | Compounding anticholinergic effects; severe risk of hyperthermia, cardiac arrhythmia, and organ failure |
| Baclofen | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Benzodiazepines | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Benzydamine | Dangerous | Compounding anticholinergic effects; severe risk of hyperthermia, cardiac arrhythmia, and organ failure |
| Bromantane | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Buprenorphine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Butylone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Caffeine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Cake | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Carisoprodol | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Clonazepam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Clonazolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Clonidine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Cocaine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Codeine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Cyclazodone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Deschloroetizolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Desomorphine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Desoxypipradrol | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Dextroamphetamine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Dextropropoxyphene | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Diazepam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Dichloropane | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diclazepam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Dihydrocodeine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Diphenhydramine | Dangerous | Compounding anticholinergic effects; severe risk of hyperthermia, cardiac arrhythmia, and organ failure |
| Ephedrine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Ephylone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Eszopiclone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| ETH-CAT | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Ethylmorphine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Ethylone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Ethylphenidate | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Etizolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| F-Phenibut | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Fenethylline | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Fentanyl | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Flualprazolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Flubromazepam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Flubromazolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Flunitrazepam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Flunitrazolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Gabapentin | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Gaboxadol | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| GBL | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| GHB | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Grayanotoxin | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Heroin | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Hexedrone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Hydrocodone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Hydromorphone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Isopropylphenidate | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Kratom | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Lisdexamfetamine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Lorazepam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| MCPP | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| MDA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| MDMA | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| MDPV | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Mephedrone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Mephenaqualone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Methadone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Methamphetamine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Methaqualone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Methcathinone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Methiopropamine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Methylnaphthidate | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Methylone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Methylphenidate | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Metizolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Mexedrone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Midazolam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Mirtazapine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Modafinil | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Morphine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Myristicin | Dangerous | Compounding anticholinergic effects; severe risk of hyperthermia, cardiac arrhythmia, and organ failure |
| N-Ethylhexedrone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| N-Methylbisfluoromodafinil | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Naloxone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| NEP | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Nicotine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Nifoxipam | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| NM-2-AI | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| O-Desmethyltramadol | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Oxiracetam | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Oxycodone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Oxymorphone | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Pentedrone | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Pentobarbital | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Pethidine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Phenobarbital | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Phenylpiracetam | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Rhodiola Rosea | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| SAMe | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| 1,3-Butanediol | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 1B-LSD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 1cP-AL-LAD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 1cP-LSD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 1cP-MiPLA | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 1P-ETH-LAD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 1P-LSD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 1V-LSD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2-Fluorodeschloroketamine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25B-NBOH | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25B-NBOMe | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25C-NBOH | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25C-NBOMe | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25D-NBOMe | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25E-NBOH | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25I-NBOH | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25I-NBOMe | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 25N-NBOMe | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-B | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-B-FLY | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-C | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-D | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-E | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-I | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-P | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-T | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-T-2 | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-T-21 | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 2C-T-7 | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3-Cl-PCP | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3-HO-PCE | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3-HO-PCP | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3-MeO-PCE | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3-MeO-PCMo | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3-MeO-PCP | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3C-E | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 3C-P | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-AcO-DET | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-AcO-DiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-AcO-DMT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-AcO-MET | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-AcO-MiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-HO-DET | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-HO-DiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-HO-DPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-HO-EPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-HO-MET | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-HO-MiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-HO-MPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 4-MeO-PCP | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 5-MeO-DALT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 5-MeO-DiBF | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 5-MeO-DiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 5-MeO-DMT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 5-MeO-MiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| 6-APB | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| AL-LAD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| ALD-52 | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Allylescaline | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Ayahuasca | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Bromo-DragonFLY | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Bufotenin | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Deschloroketamine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DET | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Dextromethorphan | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Diphenidine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DMT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DOB | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DOC | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DOI | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DOM | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| DPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Efavirenz | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Ephenidine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| EPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Escaline | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| ETH-LAD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| HXE | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Ibogaine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Inhalants | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Ketamine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| LAE-32 | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| LSA | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| LSD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| LSM-775 | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| LSZ | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Memantine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Mescaline | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| MET | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Methallylescaline | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Methoxetamine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Methoxphenidine | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| MiPLA | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| MiPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| MPT | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| MXiPr | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Nitrous | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| O-PCE | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| PARGY-LAD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| PCE | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| PCP | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| PRO-LAD | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |
| Psilocybin Mushrooms | Caution | Unpredictable compounding of hallucinogenic effects with anticholinergic delirium |